Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Apr;95(4):1650-9.
doi: 10.1172/JCI117840.

Cisplatin-associated anemia: an erythropoietin deficiency syndrome

Affiliations

Cisplatin-associated anemia: an erythropoietin deficiency syndrome

P A Wood et al. J Clin Invest. 1995 Apr.

Abstract

Cisplatin-based therapy results in a cumulative anemia that is disproportionate to the effects on other blood cells. The severity of this treatment-induced anemia and the resultant transfusion requirement in cancer patients correlate with cisplatin-induced renal tubular dysfunction. Observed/expected serum erythropoietin (EPO) ratios decline with progressive cisplatin therapy and are proportionate to the degree of renal dysfunction. Recovery from anemia and of observed/expected serum EPO ratios in patients occurs after cessation of cisplatin therapy, along with restoration of renal tubular function. Creatinine clearance, however, remains permanently depressed. Cisplatin-treated rats develop progressive renal dysfunction and anemia that persists for many weeks, without effects on white blood cell counts. The anemia is also associated with a lack of expected EPO and reticulocyte response. With EPO administration, cisplatin-treated rats exhibit a greater reticulocyte response and hematocrit increment then non-cisplatin-treated rats given EPO, indicating minimal erythroid precursor cell damage from cisplatin. These results indicate the primary etiology of cisplatin-associated anemia is a transient, but persisting EPO deficiency state resulting from cisplatin-induced renal tubular damage, which can be prevented or treated by hormone (EPO) replacement.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Am J Med. 1984 Sep;77(3):471-4 - PubMed
    1. Science. 1990 Mar 23;247(4949 Pt 1):1457-61 - PubMed
    1. Cancer. 1986 Nov 15;58(10):2214-7 - PubMed
    1. Lancet. 1986 Nov 22;2(8517):1175-8 - PubMed
    1. Cancer Res. 1987 Feb 15;47(4):983-7 - PubMed

Publication types

MeSH terms